Loxo Oncology
Jacob S. Van Naarden Chief Business Officer and CEO Joshua Bilenker
Country: USA | Funding: $506M (+)
Loxo Oncology is innovating the development of highly selective medicines for patients with genetically defined cancers. Acquired by Eli Lilly
Loxo Oncology is innovating the development of highly selective medicines for patients with genetically defined cancers. Acquired by Eli Lilly
